AbbVie (ABBV)

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ: SNY), the French healthcare titan that has spent the last five years shedding its image as a slow-moving legacy conglomerate to emerge as a [...]

As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of the year, December 31, 2025, financial markets are grappling with a stark reality: the American consumer is

AbbVie has had an impressive run over the past six months as its shares have beaten the S&P 500 by 12.4%. The stock now trades at $229.70, marking a 23.7% gain. This performance may have investors wondering how to approach the situation.

Both ETFs target short-term investment-grade bonds, but their construction determines how visible credit risk becomes when spreads move.

You don't need to settle for an average dividend yield.

As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The transition is driven by a unique convergence of high-yield dividend growth and the resolution of major "patent cliff" anxieties. With the industry preparing

After a year of steady execution and profitability, Pathward is perhaps starting to look less like a niche lender and more like a quietly scalable earnings machine.

It is wrapping up another great year, and there is no sign of a slowdown.

If you're investing for the long run, there are a myriad of companies begging to be bought.

Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025.

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results and a staggering 1,400% year-to-date rally, the French biotechnology firm has been officially crowned the most likely acquisition

Investors can expect steady dividend returns with these stocks.

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

Investors would need to have over $330,000 invested in this Vanguard dividend ETF.

AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.

The stocks listed here were all up more than 19% in 2022, while the S&P 500 crashed.

As of December 18, 2025, the financial landscape is undergoing a significant transformation, forcing retirees to reconsider their high-octane growth strategies in favor of more stable, income-generating assets. Following a year dominated by artificial intelligence speculation and aggressive tech rallies, a mid-December rotation has seen investors pulling capital away from

Can one ETF deliver decades of dividend income? This unique high-quality yield generator deserves a spot on your watchlist.

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

These habitual market beaters can pull it off again.

They could grow into their valuation over the next few years.

See what solid dividends do for a portfolio after just five years.